Anakinra: A Review of its Use in the Management of Rheumatoid Arthritis

Authors: Waugh, John; Perry, Caroline M.

Source: BioDrugs, Volume 19, Number 3, 2005 , pp. 189-202(14)

Buy & download fulltext article:

Price: $62.95 plus tax (Refund Policy)

Abstract:

Anakinra (Kineret^®) is the first biologic drug that has been developed specifically as an interleukin (IL)-1 receptor antagonist (Ra) and is derived from an endogenous IL-1Ra. The drug blocks the activity of IL-1 in synovial joints, reducing the inflammatory and joint destructive processes associated with rheumatoid arthritis (RA). In randomized, placebo-controlled trials of up to 52 weeks' duration, anakinra has shown efficacy both as monotherapy and in combination with other disease-modifying antirheumatic drugs (DMARDs) in adults with RA. It is subcutaneously administered and is generally well tolerated. Anakinra offers a useful addition to the range of drugs available for the treatment of RA.

Keywords: Adis Drug Evaluations; Anakinra; Rheumatoid arthritis

Document Type: Research article

Affiliations: 1: Adis International Inc., Yardley, Pennsylvania, USA

Publication date: 2005-01-01